**Report and Accounts** 31 March 2023
## **Research That Saves Lives**
leukaemiamyelomaresearchuk.org
Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Leukaemia and Myeloma Research UK Ltd
Company Limited by guarantee Registered number 09481278
## **Research That Saves Lives**
Leukaemia and Myeloma Research UK Ltd Unit 127, North Mersey Business Centre, Woodward Rd, Knowsley Industrial Park, Liverpool, Merseyside, L33 7UY
Tel: 0800 368 7309
Web: www.leukaemiamyelomaresearchuk.org
Email: cs@leukaemiamyelomaresearchuk.org
_Charity Number 1161622 Company Number 09481278_
Follow us on Twitter: **https://twitter.com/lmruk_org**
Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org**
MODEL CELL BIOBANK
[eleih thdi live
Together we can
beat cancer
Annual Report 2023
## **Table of contents**
|About Us ..........................................................................................................|3|
|---|---|
|Stem Cells .......................................................................................................|4|
|Charitable Activities........................................................................................|5|
|Chairman’s Report ..........................................................................................|6|
|Operation Director’s Report ...........................................................................|7|
|MCB Service..................................................................................................|9|
|Overview ......................................................................................|9|
|Case Study....................................................................................................|11|
|Research Priorities.......................................................................................|12|
|Fundraising and Volunteers.........................................................................|13|
|Thanks...........................................................................................................|14|
|Trustees and Staff ........................................................................................|14|
|Accounts .......................................................................................................|15|
https://leukaemiamyelomaresearchuk.org 2
## **About Us**
_Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer through more effective treatment in the future. We are willing to fight blood cancer regardless of how long it might take._
Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.
Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That’s around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that’s 13 every day!
We are aiming to become the UK’s leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children’s future health by storing their cord blood stem cells at the time of birth.
There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma.
treat patients with blood cancer, particularly through stem cell transplants. We do this by:
The blood is made up of three different types of cells:
• Red blood cells which carry the oxygen around the body • White blood cells which fight and stop infections
• Actively supporting stem cell research into blood cancers • Raising awareness of stem cell therapies
• Platelets which help the blood to clot
• Provide information about blood cancers and treatment options
The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.
• Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby’s umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they’re a suitable match.
In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to
This service is called Model Cell Biobank (MCB).
3 Tel: 0800 3687309
## **Stem Cells**
_In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues._
Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.
For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.
## **Where are stem cells found?**
There are four known accessible sources of autologous adult stem cells in humans:
• Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.
• Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.
• Adipose tissue (lipid cells), which requires extraction by liposuction
cancers, such as sickle cell anaemia and aplastic anaemia.
• Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.
For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia’s, the treatments use allogeneic stem cell transplants (someone else’s stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.
## **What can stem cells be used for today?**
There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.
However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia’s and solid tumours) that are treated using autologous stem cells (using your own stem cells).
There are other blood disorders that can be treated with stem cells that aren’t
https://leukaemiamyelomaresearchuk.org 4
## **Charitable Activities**
Providing Information Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.
We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.
## Medical Research
Leukaemia & Myeloma Research UK Ltd allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
Our current funding priorities are to advance understanding of stem cells and how they can
be used to treat blood cancer patients. All grant applications are reviewed by the Charity’s Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.
## Fundraising Activities
Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work.
In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has secured £127,500 of funding to support our services and help in the fight against cancer.
Model Cell Biobank Service This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.
The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.
5 Tel: 0800 3687309
## **Chairman’s Report**
It remains one of our key focuses, to widen awareness of blood cancer. We have achieved this in a number of ways.
In May, the Charity engaged in World Blood Cancer Day, sharing informative posts on social media and producing an article for Charity Today. Following this, in June we marked National Myeloma Awareness week, where we shared our informative blog ‘What is Myeloma?’ to help raise awareness of the signs and symptoms.
A poll carried out by leading charities found that out of 2,000 participants only 1% were able to name the 4 main symptoms of leukaemia. This highlighted the urgent need to raise public awareness of the symptoms of this type of blood cancer. In response, during Blood Cancer Awareness Month in September we helped
people identify common symptoms and also raised awareness of the different treatment options available, particularly cord blood banking and its many benefits.
In November, we celebrated World Cord Blood Day, sharing information and networking with like minded bodies.
In January, we launched the School Textile Recycling Scheme in the Liverpool and Greater Manchester areas. The team have been working hard to engage with schools and spread the message.
In March we celebrated Myeloma Awareness Month by educating people about this form of blood cancer and the common symptoms to look out for. We teamed up with former NHS worker and myeloma survivor, Jan Cashen (pictured above) and the West Lancs & Merseyside Myeloma
Support Group, to promote the importance of funding blood cancer research and the value of support groups to those being treated or recovering from the disease.
I would like to take this opportunity to thank all our volunteers and fundraisers without their support we wouldn’t be able to continue to offer the services that we do.
Sergejs Vinogradovs Chair, Leukaemia and Myeloma Research UK Ltd
https://leukaemiamyelomaresearchuk.org 6
## **Operation Director’s Report**
I would like to start by celebrating our inaugural winners of the charities Fundraiser of the Year award, Elaine and Peter Kinsella. They raised an incredible £8,000 for three charities.
We have had some fantastic fundraising efforts this year from walking and cycling to skydives! To give a few examples, 21-year-old Ben Saunders (pictured below) took part in an epic skydiving challenge to raise money for Leukaemia & Myeloma Research UK Ltd in memory of childhood friend, William Pearce.
For the first time ever we secured places in the London to Brighton Charity Bike Ride in September 2022. We were incredulous at the response - with 74 riders taking part, including 50 employees from professional machinery and service provider Lister Wilder. The Lister Wilder Team
raised £22,250 which LMRUK are honoured to have allocated to a grant named the Lister Wilder Research Grant (pictured right). Someone who knows the importance of our research work is Research Review Committee member, Dr Rhys Morgan. Dr Morgan raised more than £1,400 in the ride, which he completed in memory of his younger brother David.
Further support came from members of the congregation at a church in Coventry have helped to raise over £5,000 for blood cancer research in memory of a much-loved member of their congregation who passed away from the disease.
We were fortunate to be awarded some corporate support including becoming Charity of the Year for Bognor Regis Golf Club. Ladies
Captain, Heather Tidy, kindly secured £2,767 over the year.
A Scottish recruitment company celebrated its 35th birthday in business with a £3,000 donation.
We were fortunate to be one of the 20 good causes the Orion Group, headquartered in Inverness, who donated a total of £35,000 to, as a way of marking its anniversary.
Our cord blood banking service continues to grow from strength to strength. At the turn of the year we began a partnership with Smart Cells
**----- Start of picture text -----**
Tel: 0800 3687309
**----- End of picture text -----**
7
International to procure, process and store cord blood stem cells through LMRUK’s cord blood banking service, which we call MCB.
We are extremely grateful to the generous funding received from Fundraising Support Ltd who have helped this service support even more families.
Much Loved is a special memorial website in tribute to loved ones, where people can share thoughts and stories with family and friends. Through this scheme, donations can be made to charity. We are incredibly grateful to all the donations we have received this year in memory of loved ones.
I would like to say a huge ‘thank you’ to all our fundraisers for their hard work and to our dedicated staff team and partners who have pulled together to make 202223 such a huge success. All of our fundraisers are important - we simply would not be able to run these services without their help.
**Dr Joanna Tilley** Operations Director, Leukaemia and Myeloma Research UK Ltd
https://leukaemiamyelomaresearchuk.org 8
## **MCB Service**
## **Overview**
**The Model Cell Biobank (MCB)** service allows the storage of a child’s umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson’s disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.
When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future.
the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.
The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing Benefit, Council tax or Universal Credit (at least one of these) and must meet the following criteria:
• The stem cells will be used to treat the child, or another member of the family, for a medically attested treatment; • There is a history of cancer in the immediate family.
We recently extended the project to support low-income families by implementing a part funded service for those who have medical history, but are not on benefits.
Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence.
Smart Cells has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.
Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.
The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches
Tel: 0800 3687309
9
## **Advantages of Cord Blood Stem Cells**
Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.
The stem cells in your baby’s cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders. Cord blood stem cells have many advantages including: • They are easily available, having already been harvested and stored;
## **Future Plans**
• Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.
• A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;
• Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stemcell collection, such as bone marrow;
There are now a number of stem cells banks in the UK and interest in private storage has grown considerably over the last few years.
However, this is hugely expensive and means many people cannot take advantage of this service as the cost is too prohibitive.
There is also a huge shortage of stem cells being collected from BME communities - leaving them vulnerable and without a choice of treatment should they fall ill with blood cancer or another disease. Those from a minority ethnic background have only a 37% chance of finding a bone marrow match from an unrelated donor, whereas
someone from a white Caucasian background has a 72% chance.
For this reason, over the next financial year we are promoting our funded stem cell collection and storage service to BME communities to increase awareness of stem cell treatments and encourage donations from this sector.
https://leukaemiamyelomaresearchuk.org 10
## **Case Stud – Natalia’s Stor y y**
The Cord Blood Stem Cell Pilot project was launched in 2017 and since this time we have received nearly 300 enquiries – which far exceeded our expectations. To date, this has resulted in 36 successful cord blood stem cell extractions.
Our very first client was Natalia and this is her story: I am 24 years old and have 3 children aged six, three, and six months old. Whilst pregnant with my third child, I was diagnosed with lymphoma cancer in my neck. When I found out that I had cancer I was filled with guilt for my children – I was so worried that this could be hereditary and passed onto them. After doing some research into my family, I found out that my auntie had been diagnosed with cancer and that my grandfather had died from it. I had to do something to protect my children.
Cord blood stem cell storage and transplants are very costly so many cannot afford to use this potentially lifesaving service. This would certainly have been the case for us, however Leukaemia & Myeloma Research UK Ltd’s Model Cell Biobank offers a fully-funded service to qualifying families. If it wasn’t for this service we would never have been able to afford to store our baby’s cord
of whom should be a strong match should any of them ever need it.
## blood stem cells.
The process was really straightforward, we were sent a kit which contained all the information that we needed for the cord blood storage and collection.
Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother’s worst nightmare.
When I went into labour, a phlebotomist came to the hospital and waited until the baby was delivered. Then they took a sample of cord blood to collect the stem cells, which caused no harm or pain to our baby or myself, and packaged it safely and securely.
I am incredibly grateful to have found out about this potentially lifesaving service, and even if we don’t use the stored cord blood stem cells, it is reassuring to know that they will not go to waste.
My reason for storing my son’s cord blood stem cells is not for my use but for my children, all
11 Tel: 0800 3687309
## **Research Priorities**
team at the Department of Medicine at the University of Oxford £25,000 to engineer and screen different antibodies to find a way to stop mutations in the FLT3 protein from causing Acute Myeloid Leukaemia (AML) in patients.
Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
“On average less than 15% of AML patients will survive longer than five years. FLT3 is a significant contributory factor, it’s really pushing this disease and we have to shut it down,” said Dr Fernandes.
The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants. In July 2022 we awarded Dr Ricardo Fernandes and his
The grant money will help the team move the research forward more quickly and
allow them to focus all their attention over the next year on tackling the FLT3 receptor problem.
It will ultimately help in the development of a prototype for a drug that can be used as an effective treatment in the future. Dr Ricardo Fernandes hopes that moving forward, this type of research could be applicable to other types of cancer as well.
## **Dr Rhys Morgan**
## **Dr Paul Spencer Hole**
Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.
Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.
## **Professor Joseph R. Slupsky**
Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.
## **Dr Claire Seedhouse**
Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.
## **Dr Ceri Bygrave**
A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.
## **Dr John Jones**
Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings **Dr Salvatore Papa** College Hospital NHS Trust, London and An Associate Professor at Leeds University whose Eastbourne District General Hospital. research speciality is in lymphoma and myeloma.
https://leukaemiamyelomaresearchuk.org 12
## **Fundraisin and Volunteers g**
## _Churchgoers fundraising campaign in memory of a much-loved friend and wife._
Members of the congregation at a church in Coventry have helped to raise over £5,000 for blood cancer research charity, Leukaemia & Myeloma Research UK Ltd (LMRUK) in memory of a much-loved member of their congregation who passed away from the disease.
Pat Elliman from Coventry was about to begin a round of stronger chemotherapy treatment for Acute Myeloid Leukaemia (AML) in hospital in December 2020 when she passed away in the arms of her devoted husband Malcolm.
Well known for her generous and kind nature, as well as a talent for baking, Pat was an active member of Holyhead Road United Reformed Church in the city for many years. Since her death, other members of the church have been holding a range of fundraising events after selecting LMRUK as its chosen charity for 2022.
The fundraising effort has been coordinated by Karen Adams, supported by her mum, Sue Adams and Malcolm. It was
August 2020 and Pat had just given her 97th donation of blood when she arrived back home feeling very tired. Within a few days, blood tests and a bone marrow analysis revealed she had incurable AML FLT3 WILD.
emergency admissions for infections. It was only two days before her death that she was told her condition was worsening and she chose to undertake the stronger chemotherapy treatment. Malcom says “I could write a book about Pat’s trials and bravery during those five months but also understand that many people have the same experience. The haematology staff were incredibly kind and caring throughout and I can’t thank them enough. “I am grateful that the church Pat loved so much is raising money for LMRUK in memory of her, but also to help other sufferers. I will do everything I can to support this fundraising,”
Malcom has already been part of the fundraising effort by doing a sponsored walk from Coventry to Kenilworth, a walk he and Pat would often do. Other fundraising events have included quiz and bingo evenings, a sponsored spell event by members of the 7th Coventry Girls’ Brigade Company, a secondhand book sale at a local shopping centre, craft and cake sales.
Karen and fellow family members completed a sponsored step challenge while on holiday in Devon. They set themselves a target of 600,000 in eight days and managed over 900,000.
During the Covid-19 pandemic she endured three courses of chemotherapy over several months, much of which had to take place at her home because of lockdown restrictions. But she also had to endure many visits to hospital for treatment, including two
“We were originally aiming to raise £4,000, but our current total is over £5,000 – the highest amount we have raised for a chosen project”, said Karen. The cheque was presented to LMRUK in January 2023.
13 Tel: 0800 3687309
## **Thanks to Funders**
- Chamifealion Charitable Trust
- Boden
- Albert Hunt Trust
- Tesco Groundworks
- Ambergate Charitable Trust
- Ladbrokes Coral
- May Hearnshaw Charitable Trust
- T K Maxx and Homesense
- Santa Barbara Heights Charitable Trust
- LPC Group
- Thomas Sivewright Catto Charitable Settlement
- Ian Askew Charitable Trust
- Grace Trust
- Henhurst Trust
- The Tony Bramall Charitable Trust
- Family Rich Charities Trust
- Gisela Graham Foundation
- Stella Symons
- Gledswood Charitable Trust
- Marsland Mcadoo
- Dorothy Holmes Charitable Trust
- Orion Group (see photo)
- Arnold Clark Community Fund
## **Staff and Committee Members**
## **Trustees 2022-2023**
- Sergejs Vinogradovs (Chair)
- Tatjana Vinogradova
- Victoria Kieran
- Julija Sidorika
## **Thanks to Individuals and supporters**
- Best Freelance Design Ltd
- Smart Cells International
- Dr Hannah Hunter – Consultant Haematologist
- Fundraising Support Ltd
- KOR Communications Limited
## **Staff Team**
- Dr Joanna Tilley - Interim Operations Director
- Lucy Heron - Office Manager / Senior MCB Call Centre Manager
- Phlebotomy UK Ltd
- Research Review Committee
- Richard Thompson - Call Centre
- Kate Williams - PT Fundraiser
https://leukaemiamyelomaresearchuk.org 14
Income and Expenditure Account for the year ended 31st March 20�3
## **Accounts**
leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Company Limited by guarantee Registered number 09481278
## **Accounts 31 March 20�3**
15
## **Leukaemia & Myeloma Research UK Ltd**
## **Report and accounts for the year ended 31 March 2023**
## **Contents**
||**Page**||
|---|---|---|
|**Charity information**||1|
|**Trustees' Annual Report**||1|
|**Statement of directors' responsibilities**||5|
|**Independent Examiner's Report**||7|
|**_Funds Statements:-_**|||
|Statement of Financial Activities||9|
|Statement of Financial Activities - Prior Year statement||10|
|Movements in funds||12|
|Income and Expenditure account||13|
|**Balance sheet**||14|
|**Notes to the accounts**||15|
## **Leukaemia & Myeloma Research UK Ltd**
Company Registration Number - 09481278
## **Trustees' Annual Report for the year ended 31 March 2023**
The Trustees present their Report and Accounts for the year ended 31 March 2023, which also comprises the Directors' Report required by the Companies Act 2006.
## **Reference and administrative details**
## _**The charity name.**_
The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.
The charity is also known by its operating name, LMR UK Ltd.
## _**The charity's areas operation and UK charitable registration.**_
The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.
The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.
The charity does not operate in any overseas jurisdictions.
## _**Legal structure of the charity**_
The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.
The governing document is dated 10 March 2015
There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.
By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.
The trustees are all individuals.
1
## **Leukaemia & Myeloma Research UK Ltd**
Company Registration Number - 09481278
## **Trustees' Annual Report for the year ended 31 March 2023**
## **The principal operating address, telephone number, email and web addresses of the charity**
Unit 127, North Mersey Business Centre Woodward Road, Liverpool Merseyside, L33 7UY Telephone 08003687309 Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/
The registered office of the charity for Companies Act purposes is the same as the operating address shown above.
## **The Trustees in office on the date the report was approved were:-**
Sergejs Vinogradovs Tatjana Vinogradova Julija Sidorika Victoria Kieran
## **The following persons served as Trustees during the year ended 31 March 2023 :-**
The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.
All the trustees are also members of the charity.
## **Objects and activities of the charity**
## _**The purposes of the charity as set out in its governing document.**_
The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:
1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.
2
## **Leukaemia & Myeloma Research UK Ltd**
Company Registration Number - 09481278
## **Trustees' Annual Report for the year ended 31 March 2023**
## **Structure, governance and management of the charity**
## _**The methods used to recruit and appoint new charity trustees.**_
Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.
Accountants
KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT
3
## **Leukaemia & Myeloma Research UK Ltd**
Company Registration Number - 09481278
## **Trustees' Annual Report for the year ended 31 March 2023**
## **Financial review**
|Restricted Revenue Funds
**Total Funds**
Unrestricted Revenue Funds available for the
general purposes of the charity
**Net income**|**2023**
**£**
35,474
311,735
40,586
352,321|**2022**
**£**
30,559|
|---|---|---|
|||285,330
31,517|
|||316,847|
## _**Financial review of the position at the reporting date, 31 March 2023 .**_
Overall surplus stands at £352,321 and will be distributed in following way: £150,000 for the Reserves; £65,000 for Research grants, and £137,321 for charity development, including MCB and the e-shop.
The trustees consider the financial performance by the charity during the year to have been satisfactory.
## _**Policies on reserves.**_
The trustees collectively aim to maintain free reserves in unrestricted funds within a range equivalent to twelve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees to ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy will undergo an annual review, aligning with the scrutiny of the charity's annual accounts.
In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the trustees have determined that a prudent Reserves amount must be set at £150,000. This decision is reflective of the charity's commitment to financial resilience and its responsiveness to the evolving economic landscape.
## _**Availability and adequacy of assets of each of the funds**_
The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.
## **Details of The Independent Examiner**
Olivia Higgins FCCA
Member of Chartered Certified Accountants 255 Poulton Road Wallasey Wirral
CH44 4BT
4
## **Leukaemia & Myeloma Research UK Ltd**
Company Registration Number - 09481278
## **Trustees' Annual Report for the year ended 31 March 2023**
## **Statement of the Directors Trustees' Responsibilities**
The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .
In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-
- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of
recommended practice have been followed, subject to any material
departures disclosed and explained in the financial statements;
The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.
The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.
5
Leukaemia & Myeloma Research UK Lld
Coryany Redstralion Nber. 09481278
Trust88s' Annual Report tor the year 8nded 31 March 2023
meld ot preparation of a¢counts- Small company provlsiong
Thè flnanclal slalem&nts are sel out on pages 9 10 33.
The linan¢ial statements have been prepar8d imKAemenllro Iho FRS 102 SORP IStal8m&nt of
Recommend1 Practice for Accounllng and Rewrling by Charrflesl 2015. las amend1 by thg
Bulletin iss{J1 in Oclobgr 2018 and applicab lo a(tounting p9rths beginnlng on or aftor fjst
January 20191, trho SORPI, ar¥J in atXorthrO wlh the Financkil Repor Standard 102,
1gffe¢dv¢ 1st January 20181
Thgse flnancial slal8menls have been prepared in actordance lh8 provtsions in P8Jl 15 01 th
ConN)anios Act 2006. applicablè to eornpanies sthject lo th8 small companies reglm&.
Thls report was aFprov&l by th8 board of trusieos on l/IDIAm6u2023.
TATJANA VINIXRADOVA
Diiedor aJKI TriJst8e
## **Leukaemia & Myeloma Research UK Ltd**
## **Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2023**
I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2023 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15.
## **Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report**
As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.
The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.
Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-
a) examine the financial statements of the charity under Section 145 of the Act;
b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.
## **Basis of Independent Examiner's Statement and scope of work undertaken**
Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies.
I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.
The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide
Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.
I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.
7
Leukaemla & Myeloma Research UK Ltd
Ind8pendonl Exomlngrf8 Stalernent, Report aThl Oplnlon
Subla(# to tha Ilmitaliors upon SLV¢ of my as detsilwl atrn, I have Lxyryleted nw 8xamlnalh)n'. arnl ¢an
¢onllrrn Ihat'.-
The arts)uNs ol this rtharil*Jle cryany aro not I1c{l to aLxSted Part 16 of t1 ColanIeS Acl 2006.
Thiq is a rrt In reSpt of an exan*albn ¢arried wi und8T 145 of the in aordaI wh DIrecon8
given by the Cl4rfty CoTrffji8gon uTrJer s8Cth)n 145(5llbl of may te applicat4e'
and ttrAt no MarE rnaitèri have cm to my attenlkn kn vilh exam1rOn giving me cause to
bolleve that In any rnaleriaj respecl-.
)xunUng rettwds were not k1 in resF*tt ol the tharity as raqrj by Sethon 3B6 of the CorJanIeS Ad
21x6 aTrJ Seclkjn 130 01 Tha P**Unrestricted**
**Funds**
**2023**
**£**
**Income & Endowments from:**
Donations & Legacies
A1
138,590
Charitable activities
A2
18,635
Investments
A4
665
Other
A5
50,063
**Total income**
**A**
**207,953**
**Expenditure on:**
Raising funds
B1
19,100
Charitable activities
B2
162,448
**Total expenditure**
**B**
**181,548**
**Net income for the year**
**26,405**
**Transfers between funds**
**C**
-
**Net income after transfers**
**A-B-C**
**26,405**
**26,405**
**Reconciliation of funds:-**
**E**
**Total funds brought forward**
285,330
**Total funds carried forward**
**311,735**
**SORP**
**Ref**
**Net movement in funds**|**Current year**
**Restricted**
**Funds**
**2023**
**£**
35,385
1,918
-
-
**37,303**
-
28,234
**28,234**
**9,069**
-
**9,069**
**9,069**
31,517
**40,586**|**Current year**
**Total Funds**
**2023**
**£**
**173,975**
**20,553**
**665**
**50,063**
**245,256**
**19,100**
**190,682**
**209,782**
**35,474**
**-**
**35,474**
**35,474**
**316,847**
**352,321**|**Prior Year**
**Total Funds**
**2022**
**£**
138,627
17,846
27
50,109|
|---|---|---|---|
||||**206,609**|
||||9,095
166,955|
||||**176,050**|
|||||
||||**30,559**
-|
||||**30,559**|
||||**30,559**
286,288|
||||**316,847**|
The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.
A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.
All activities derive from continuing operations
**The notes attached on pages 15 to 33 form an integral part of these accounts.**
9
## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023**
## **Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP**
|**Income & Endowments from:**
Donations & Legacies
A1
Charitable activities
A2
Investments
A4
Other
A5
**Total income**
**A**
**Expenditure on:**
Raising funds
B1
Charitable activities
B2
**Total expenditure**
**B**
**Net income for the year**
**Net income after transfers**
**Reconciliation of funds:-**
**E**
**Total funds brought forward**
**Total funds carried forward**
**Net movement in funds**
**SORP**
**Ref**|**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
126,387
17,846
27
50,109
194,369
9,095
153,973
**163,068**
31,301
31,301
**31,301**
258,527
**289,828**
|**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
12,240
-
-
-
-
12,240
-
12,982
**12,982**
(742)
(742)
**(742)**
27,761
**27,019**|**Prior Year**
**Total Funds**
**2022**
**£**
**138,627**
**17,846**
**27**
**50,109**
**206,609**
**9,095**
**166,955**
**176,050**
30,559
30,559
**30,559**
**286,288**|
|---|---|---|---|
||||**316,847**|
## **All activities derive from continuing operations**
A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'
**The notes attached on pages 15 to 33 form an integral part of these accounts.**
10
## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023**
## **Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2023 towards fixed assets for Charity use:-**
|**2023 towards fixed assets for Charity use:-**|||
|---|---|---|
|Funds generated in the year as detailed in the SOFA
Resources applied on functional fixed assets
**Net resources available to fund charitable activities**|**2023**
**£**
35,474
(1,599)
**33,875**|**2022**
**£**
30,559
-|
|||**30,559**|
The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.
## **The notes attached on pages 15 to 33 form an integral part of these accounts.**
11
## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023**
## **Movements in revenue and capital funds for the year ended 31 March 2023**
## **Revenue accumulated funds**
|**Unrestricted**
**Funds**
**2023**
**£**
Accumulated funds brought forward
285,330
26,405
**311,735**
(From)/To unrestricted revenue funds
-
**Closing revenue funds**
**311,735**
**Summary of funds**
**Unrestricted**
**and**
**Designated funds**
**2023**
**£**
Revenue accumulated funds
311,735
Recognised gains and losses before
transfers|**Restricted**
**Funds**
**2023**
**£**
31,517
9,069
**40,586**
-
**40,586**
**Restricted**
**Funds**
**2023**
**£**
40,586|**Total**
**Funds**
**2023**
**£**
316,847
35,474
**352,321**
-
**352,321**
**Total**
**Funds**
**2023**
**£**
**352,321**|**Last year**
**Total Funds**
**2022**
**£**
**286,288**
30,559|
|---|---|---|---|
||||**316,847**
-|
||||**316,847**|
||||**Last Year**
**Total Funds**
**2022**
**£**
316,847|
**The notes attached on pages 15 to 33 form an integral part of these accounts.**
12
## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023**
## **Leukaemia & Myeloma Research UK Ltd Income and Expenditure Account for the year ended 31 March 2023 as required by the Companies Act 2006**
|**_Income_**
Income from operations
Interest receivable
Other operating income
**Gross income in the year before exceptional items**
**Gross income in the year including exceptional items**
**_Expenditure_**
Charitable expenditure, excluding depreciation and amortisation
Depreciation and amortisation
Fundraising costs
Governance costs
**Total expenditure in the year**
Tax on surplus on ordinary activities
**Retained surplus for the financial year**
**Net income after tax in the financial year**
**Net income before tax in the financial year**|**2023**
**£**
194,528
665
50,063
**245,256**
**245,256**
189,657
1,025
19,100
-
**209,782**
**35,474**
-
**35,474**
**35,474**|**2022**
**£**
156,405
27
50,109|
|---|---|---|
|||**206,609**|
|||**206,609**|
|||165,910
625
9,095
420|
|||**176,050**|
|||**30,559**
-|
|||**30,559**|
|||**30,559**|
All activities derive from continuing operations
In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.
## **The notes attached on pages 15 to 33 form an integral part of these accounts.**
13
Leukaomlo & Ilyetoma Research UK Ud. B919e Sheela5 at 31 PA&r¢h 21>23
2023
202
Flx¢d ass•19
Tangible &%sets
Total flxed assets
124
1m4
1,250
1,250
Curreni 88eeis
B1
17MI
17,507
4,432
299,864
321.803
Ca¥h at and In hand
Toial currnnt asso18
J,510
356.r
Crethi¢XS.' amwrrt# thvIlh ono
10 C1
15,S&31
I6.2
Nut currenta8&el•
35).497
315,597
Th8 tolal net a8$0ts of Ih•¢h4rMy
316,847
Tho lolal n•1 oflha ch8rltyer8 fwthl tythtrfuNl# ofthè clwlty. OB follws:.
Re8trkt8d fvr
RgstrIGf8d R8V8nuB Fun(k
13
31,517
31517
Unr•*irlO Fund8
Unr8Stricted Flevenw Fun(Is
13 03
311,T
285330
311.735
285,330
D881gMtBd Fund&
Tol81 chartylurhlg
316,8
Thg ECA4P Ref above 18 ts da8sWIkn of Sh88t In tho fOrTh SOFIP
doLunen15. As requlr8d by paraoraph 4.60 01 the SORP. trht forward and (aFrled lorward fynd5 abov6
have b88n agréed SOFA..
The dir8ctcxs are salsfiad thai lh8 enbllBd to 8X8rnrknn framlhe rwBMrernBnt l) Lthln an undgr
s¢ctlon 477 of the Companle5 Ac12006.
The ML$ rt requir8d th8 ottskn an authl in ac•JJrdance*lth swlkjn 476ofthe
Th8 dractors acknedge their r6spons*iltle8 for the IwurervtS ol th8 20C6
wlth resp$¢t lo a(£¥Jundng records al th8 [Sparaon of aLfOUtts.
T.w chartty IB $ublect to InderTrI0t EKaft¥naiknn un¢Je¥ L*arity Iwathn. aThJ the rep)rt of the 1Tr*8nd8nt
EKarnln8r18 on paa8 8.
linandl Stalwn[S have bgen prq)ared in 8CWrda with tr* pr¢y¢tsbw In Part 1S of the Cwanl95 l*t
2006. akable lo c(¥TFanies subj*.to the smal tmpan*S wim8.
TATJANA VIIthX4RAfK)VA
Trusteo
Apwoved tylh8 trjard of Injstees
rwJtssaUachBd on pap$ 15 to 33 loffli an rt 0fth ar
14
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
## **1 Accounting policies**
## _**Policies relating to the production of the accounts.**_
## **Basis of preparation and accounting convention**
The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.
## **Risks and future assumptions**
The charity is a public benefit entity.
This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven.
## _**Policies relating to categories of income and income recognition.**_
## **Nature of income**
Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.
## **Categories of Income**
Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.
Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.
Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.
15
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
## **Income recognition**
Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.
Dividends are accrued when the shareholder’s right to receive payment is established.
Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.
All income is accounted for gross, before deducting any related fees or costs.
## **Income from legacies**
Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.
Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.
Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.
If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities
16
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
## **Donated goods, facilities and services**
Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.
Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.
In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.
If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.
The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.
The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in _'legacies and donations_ '. Goods donated for resale are included in _'Income from other trading activities'_
The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.
Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.
All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.
## _**Policies relating to expenditure on goods and services provided to the charity.**_
## **Allocating costs to activities**
Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.
The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-
**Staffing** - on the basis of time spent in connection with any particular activity. **Staffing** - on a per capita basis, based on the number of of people employed within any partiular activity. **Premises related costs** - on the proportion of floor area occupied by a particular activity.
**Non specific support costs** - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures
**Estimation techniques** used in apportioning costs - give details
17
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
## _**Policies relating to assets, liabilities and provisions and other matters.**_
## **Stocks and work in progress**
Stock is valued at the lower of cost and net realisable value.
## **Debtors**
Debtors are measured at their recoverable amounts at the balance sheet date.
## **Creditors and provisions**
Liabilities are measured at their settlement amount. A liability is recognised for the amount the Charity anticpates it will pay to settle the deb t or the amount it has received as an advance payment for goods or services it must provide.
## **2 Liability to taxation**
The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.
## **3 Winding up or dissolution of the charity**
If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.
No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.
## **4 Defined contribution pension schemes**
Any liabilites and assets associated with the scheme are shown under debtors and creditors.
## **5 Remuneration and payments to Trustees and persons connected with them**
The trustees received payments in the amount of £1,292 as travel expenses related to providing services for clothing collection.
No persons connected with the trustees received any remuneration from the charity, or any related entity.
## **6 Trustees' expenses**
There were no Trustees' expenses in the year and in the prior year.
18
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
## **7 Tangible fixed assets**
|**_Current Year_**
**Cost**
At 1 April 2022
Additions
**At 31 March 2023**
**Depreciation**
At 1 April 2022
Charge for the year
**At 31 March 2023**
**Net book value**
**At 31 March 2023**
**At 31 March 2022**
**8**
**Stocks & Work in Progress**
Stocks before write downs
**9 Debtors**
Prepayments and accrued income
Other debtors|**Land and**
**Buildings**
£
-
-|**Plant &**
**Machinery**
£
2,500
1,599|**Motor**
**Vehicles**
£
-
-|**Total**
**Total**
£
£
2,500
2,500
1,599
1,599|
|---|---|---|---|---|
||**-**|**4,099**|**-**|**4,099**
**4,099**|
||-
-|1,250
1,025|-
-|1,250
1,250
1,025
1,025|
||**-**|**2,275**|**-**|**2,275**
**2,275**|
||**-**|**1,824**|**-**|**1,824**
**1,824**|
||||||
||**-**|**1,250**|**-**|**1,250**
**1,250**|
||||**2023**
**£**
17,490|**2022**
**£**
17,507
17,507
**2022**
**£**
485
3,947
**4,432**|
||||17,490||
||||**2023**
**£**
280
3,947||
||||**5,060**||
19
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
|**10 Creditors: amounts falling due within one year**
Trade creditors
Accruals
**11 Income and Expenditure account summary**
**At 1 April 2022**
Surplus after tax for the year
**At 31 March 2023**|**2023**
**£**
3,643
1,920|**2022**
**£**
3,916
2,290|
|---|---|---|
||**5,563**|**6,206**|
||**2023**
**£**
316,847
35,474|**2022**
**£**
286,288
30,559|
||**352,321**|**316,847**|
## **12 Particulars of how particular funds are represented by assets and liabilities**
|**At 31 March 2023**
Tangible Fixed Assets
Current Assets
Current Liabilities
**At 1 April 2022**
Tangible Fixed Assets
Current Assets
Current Liabilities|**Unrestricted**
**funds**
**£**
1,824
315,474
(5,563)|**Designated**
**funds**
**£**
-
-|**Restricted**
**funds**
**£**
-
40,586
-|**Total**
**Total**
**Funds**
**Funds**
**£**
**£**
**1,824**
**1,824**
**356,060**
**356,060**
**(5,563)**
**(5,563)**|
|---|---|---|---|---|
||**311,735**|**-**|**40,586**|**352,321**
**352,321**|
||**Unrestricted**
**funds**
**£**
1,250
290,286
(6,206)|**Designated**
**funds**
**£**
-
-
-|**Restricted**
**funds**
**£**
-
31,517
-|**Total**
**Total**
**Funds**
**Funds**
**£**
**£**
**1,250**
**1,250**
**321,803**
**321,803**
**(6,206)**
**(6,206)**|
||**285,330**|**-**|**31,517**|**316,847**
**316,847**|
20
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
**13 Change in total funds over the year as shown in Note 12 , analysed by individual funds**
|**_Unrestricted and designated funds:-_**
Unrestricted Revenue Funds
**Total unrestricted and designated funds**
**_Restricted funds:-_**
Model Cell Biobank
**Total restricted funds**
**Total charity funds**|**Funds**
**brought**
**forward from**
**2022**
**£**
285,330|**Movement in**
**funds in 2023**
**See Note 14**
**£**
26,405|**£**
**-**
**Transfers**
**between**
**funds in 2023**|**Funds carried**
**forward to**
**2024**
**£**
**£**
**311,735**
**311,735**
**Funds carried**
**forward to**
**2024**|
|---|---|---|---|---|
||**285,330**|**26,405**|**-**|**311,735**
**311,735**|
||31,517|9,069|-|**40,586**
**40,586**|
||**31,517**|**9,069**|**-**|**40,586**
**40,586**|
||||||
||**316,847**|**35,474**|**-**|**352,321**
**352,321**|
**14 Analysis of movements in funds over the year as shown in Note 13**
|**_Unrestricted and designated funds:-_**
Unrestricted Revenue Funds
**_Restricted funds:-_**
Model Cell Biobank|**Income**
**2023**
**£**
207,953
37,303|**Expenditure**
**2023**
**£**
(181,548)
(28,234)|**Gains &**
**Losses**
**2023**
**£**
-
-|**Movement**
**Movement**
**in funds**
**in funds**
**2023**
**2023**
**£**
**£**
**26,405**
**26,405**
**9,069**
**9,069**|
|---|---|---|---|---|
||**245,256**|**(209,782)**|**-**|**35,474**
**35,474**|
21
## **Leukaemia & Myeloma Research UK Ltd**
## **Notes to the Accounts for the year ended 31 March 2023**
## **15 The purposes for which the funds**
_**Unrestricted and designated funds:-**_ Unrestricted Revenue Funds
These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, research grants, and, subject to charity legislation, are free from all restrictions on their use.
_**Restricted funds:-**_ Model Cell Biobank
The purpose of these funds is described under the accounting policy.
## **16 Ultimate controlling party**
The charity is under the control of its legal members.
Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.
22
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
_**This analysis is classsified by conventional nominal descriptions and not by activity.**_
## **17 Donations, Grants and Legacies**
|**Donations, Grants and Legacies**|||||
|---|---|---|---|---|
|**Donations and gifts from individuals**
Stripe direct donations
Holyhead Road Unit Holyhead
Church
Facebook
Just Giving
Kiltwalk
In Memory
Fundraising Support
Muchloved
Virgin Money Giving
Giving.com
Paypal Giving
Small donations individually less than £1000
**Total donations and gifts from**
**individuals**
Refunds from HMRC on gift aided donations|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
8,415
-
14,707
6,536
2,523
47,846
2,880
17,856
-
7,859
-
2,646
2,895|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
-
-
-
-
-
-
-
-
-
-
-
-
**-**|**Current year**
**Total Funds**
**2023**
**£**
**8,415**
**-**
**14,707**
**6,536**
**2,523**
**47,846**
**2,880**
**17,856**
**-**
**7,859**
**-**
**2,646**
**2,895**
**114,163**|**Prior Year**
**Total Funds**
**2022**
**£**
7,410
68
7,995
-
3,782
17,827
1,193
9,028
-
3,545
2,453
2,379
1,066|
||**114,163**|||**56,746**|
All the donations and gifts in the prior year were unrestricted.
## **Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis**
||**Prior Year**|**Prior Year**|**Prior Year**|
|---|---|---|---|
||**Unrestricted**|**Restricted**|**Total Funds**|
||**Funds**|**Funds**||
||**2022**|**2022**|**2022**|
||**£**|**£**|**£**|
|**Prior year**|**44,506**|**12,240**|**56,746**|
23
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
|**Legacies receivable**
**Legacies receivable**
Small legacies individually less than
£1000
Mrs Mary Dallas
Mrs Beryl Mary Round
Mayo Wynne Baxter Solicitors
Sylvia Allanson
Malcolm Squibb
**Legacies receivable - Prior Year analysis**
**Prior year**
**Total legacies receivable**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
-
-
-
-
1,500
5,000|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
-
-
-
-
-
**-**
**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-|**Current year**
**Total Funds**
**2023**
**£**
**-**
**-**
**-**
**-**
**1,500**
**5,000**
**6,500**
**Prior Year**
**Total Funds**
**2022**
**£**
**40,948**|**Prior Year**
**Total Funds**
**2022**
**£**
-
100
40,784
64
-
-|
|---|---|---|---|---|
||**6,500**|||**40,948**|
||**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
40,948||||
24
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **Revenue grants from government and public bodies**
|Small grants individually less than
£1000
Irwin Mitchell LLP / Ambergate
Santa Barabara Heights Cjaritable
Trust
Thomas Sivewright Catto Charitable
Trust
The Tony Bramall Charitable Trust
The Family Rich Charities Trust
L&R Gilley Charitable Trust
Gisela Graham Foundation
The Constance Paterson Charitable
Trust
The Ian Askew Charitable Trust
Charities Trust AVIVA
Crowdfunder
The Caron Keating Foundation
The Hospital Saturday Fund
May Nearnshaw Charitbale Trust
Ladbrokes Coral Trust
The Gledswood Charitable Trust
Dorothy Homes Charitable Trust
CAF/Box Power Foundation
The Thomas Sivewright Catto
Charitable Trust
Sir Cliff Richard
Albert Hunt
Arnold Clark
**Total public sector revenue grants**
**Revenue grants from government and**
**public bodies**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
2,500
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1,000
1,000|**Current year**
**Restricted**
**Funds**
**2023**
**£**
200
2,000
1,000
1,000
1,000
5,000
-
2,000
-
1,000
-
-
-
-
2,000
2,500
5,000
5,000
-
-
-
-
**27,700**|**Current year**
**Total Funds**
**2023**
**£**
**2,700**
**2,000**
**1,000**
**1,000**
**1,000**
**5,000**
**-**
**2,000**
**-**
**1,000**
**-**
**-**
**-**
**-**
**2,000**
**2,500**
**5,000**
**5,000**
**-**
**-**
**-**
**1,000**
**1,000**
**32,200**|**Prior Year**
**Total Funds**
**2022**
**£**
1,240
-
-
-
-
-
2,500
-
2,500
1,000
3,268
247
3,000
2,000
10,000
1,000
1,000
1,000|
|---|---|---|---|---|
||**4,500**|||**28,755**|
**Revenue grants from government and public bodies - Prior Year analysis**
|**Prior Year**|**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
28,755|**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-|**Prior Year**
**Total Funds**
**2022**
**£**
**28,755**|
|---|---|---|---|
25
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
|Lunya Limited
Fundraising Support Ltd
**Total private sector revenue grants**
Theatrical Society
LPC Group
**Revenue grants and donations from non**
**public bodies**
Orion Engineering|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
-
-
10,000
427
3,000|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
7,685
-
-
-
**7,685**|**Current year**
**Total Funds**
**2023**
**£**
**-**
**7,685**
**10,000**
**427**
**3,000**|**Prior Year**
**Total Funds**
**2022**
**£**
8,000
4,178
-
-
-
**12,178**|
|---|---|---|---|---|
||**13,427**||**21,112**||
**Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis**
|**Prior Year**|**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
12,178|**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-|**Prior Year**
**Total Funds**
**2022**
**£**
**12,178**|
|---|---|---|---|
26
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **Total Donations, Grants and Legacies**
|**Total Donations, Grants and Legacies**|||||
|---|---|---|---|---|
|**_Current year_**
**Unrestricted**
**Funds**
**2023**
**£**
**Total Donations, Grants and**
**Legacies**
**A1**
**138,590**
All the donations and gifts in the prior year were unrestricted.
**_Prior year_**
**Unrestricted**
**Funds**
**2022**
**£**
**Total Donations, Grants and**
**Legacies**
**A1**
**126,387**|**Unrestricted**
**Funds**
**2023**
**£**|**Restricted**
**Funds**
**2023**
**£**
**35,385**
**Restricted**
**Funds**
**2022**
**£**
**12,240**|**Current Year**
**Total Funds**
**2023**
**£**
**173,975**
**Prior Year**
**Total Funds**
**2022**
**£**
**138,627**|**Prior Year**
**Total Funds**
**2022**
**£**|
||**138,590**|||**138,627**|
||||||
||**126,387**||||
27
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **18 Income from charitable activities - Trading Activities**
|**18 Income from charitable activities - Trading Activiti**|**es**||||
|---|---|---|---|---|
|**_Current year_**
**Primary purpose and ancillary trading**
**_Prior year_**
**Primary purpose and ancillary trading**
**Total Primary purpose and ancillary trading**
**19**
**_Current year_**
Total income from charitable trading
**Total from charitable activities**
**A2**
**Income from charitable activities - Prior Year analysis**
**_Prior year_**
Total income from charitable trading
Sale of goods and services in accordance
with the charity's objects
**Total Primary purpose and ancillary**
**trading**
Sale of goods and services in accordance
with the charity's objects
**Total Income from charitable activities**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
18,635|**Current year**
**Restricted**
**Funds**
**2023**
**£**
1,918
**1,918**
**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-
**-**
**Current year**
**Restricted**
**Funds**
**2023**
**£**
1,918
**1,918**
**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-
**-**|**Current year**
**Total Funds**
**2023**
**£**
**20,553**
**20,553**
**Prior Year**
**Total Funds**
**2022**
**£**
**17,846**
**17,846**
**Current year**
**Total Funds**
**2023**
**£**
**20,553**
**20,553**
**Prior Year**
**Total Funds**
**2022**
**£**
17,846
**17,846**|**Prior Year**
**Total funds**
**2022**
**£**
17,846|
||**18,635**|||**17,846**|
||**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
17,846|||**Prior Year**
**Total Funds**
**2022**
**£**
17,846|
||**17,846**||||
||**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
18,635||||
||**18,635**|||**17,846**|
||**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
17,846||||
||**17,846**||||
28
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **20 Investment income**
|**20 Investment income**|||||
|---|---|---|---|---|
|Bank Interest Receivable
**Total investment income**
**A4**
**21 Other income and gains**
**_Current year_**
**Total other income**
**A5**
**Other income and gains - Prior year analysis**
**_Prior Year_**
**Total other income**
**A5**
Royalties from the exploitation of intellectual
property rights
Sundry other income
Royalties from the exploitation of intellectual
property rights
Sundry other income|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
665|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
**-**
**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
-
**-**
**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-
-
**-**|**Current year**
**Total Funds**
**2023**
**£**
**665**
**665**
**Current year**
**Total Funds**
**2023**
**£**
**50,063**
**-**
**50,063**
**Prior Year**
**Total Funds**
**2022**
**£**
**50,000**
**109**
**50,109**|**Prior Year**
**Total Funds**
**2022**
**£**
27|
||**665**|||**27**|
||**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
50,063
-|||**Prior Year**
**Total Funds**
**2022**
**£**
50,000
109|
||**50,063**|||**50,109**|
||**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
50,000
109||||
||**50,109**||||
29
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **22 Expenditure on charitable activities - Direct spending**
|**_Current Year_**
**Total direct spending**
**B2a**
**_Prior Year_**
**Total direct spending**
**B2a**
Costs of activities and events
Travel and Subsistence - Charitable
Activities
Costs of activities and events
Consultancy and professional support
Consultancy and professional support
Travel and Subsistence - Charitable
Activities
Travel and Subsistence - Trustees
Travel Expenses|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
218
11,559
33,333
1,292|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
25,102
-
-
**25,102**
**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
-
10,585
-
**10,585**|**Current year**
**Total Funds**
**2023**
**£**
**218**
**36,661**
**33,333**
**1,292**
**71,504**
**Prior Year**
**Total Funds**
**2022**
**£**
**1,931**
**20,683**
**24,636**
**47,250**|**Prior Year**
**Total Funds**
**2022**
**£**
**1,931**
**20,683**
**24,636**
**-**|
|---|---|---|---|---|
||**46,402**|||**47,250**|
||**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
1,931
10,098
24,636||||
||**36,665**||||
30
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **23 Expenditure on charitable activities - Charitable trading**
|**_Current Year_**
**Total charitable trading costs**
**B2b**
Cost of goods for primary purpose trading -
Including movement in stock for goods
made by beneficiaries|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
**7,874**|**Current year**
**Restricted**
**Funds**
**2023**
**£**
**-**
**-**|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2023**
**2022**
**£**
**£**
**7,874**
**11,198**|
|---|---|---|---|
||**7,874**||**7,874**
**11,198**|
## **24 Expenditure on charitable activities- Grant funding of activities**
|**_Current Year_**
**Total grantmaking costs**
**B2c**
Grants made to organisations|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
25,000|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
**-**|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2023**
**2022**
**£**
**£**
**25,000**
**24,251**|
|---|---|---|---|
||**25,000**||**25,000**
**24,251**|
31
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **25 Support costs for charitable activities**
|**25**
**Support costs for charitable activities**|||
|---|---|---|
|**Current year**
**Current year**
**_Current Year_**
**Unrestricted**
**Funds**
**Restricted**
**Funds**
**2023**
**2023**
**£**
**£**
**_Premises Expenses_**
Rates and water charges
219
-
Rent and rates
24,212
-
17
-
-
-
686
-
596
-
**_Administrative overheads_**
2,184
-
698
-
1,480
-
Shipping, freight and delivery
-
-
Membership subscriptions
7,895
-
2,199
-
1,099
-
2,119
1,979
10,603
1,143
-
-
**_Professional fees paid to advisors other than the auditor or examiner_**
710
-
26,735
10
660
-
**_Financial costs_**
35
-
1,025
-
**Support costs before reallocation**
**83,172**
**3,132**
**Total support costs - Current Year**
**83,172**
**3,132**
The basis of allocation of costs between activities is described under accounting policies
Bank charges
Accountancy fees other than
examination or audit fees
Management fees
Property insurance
Light heat and power
Telephone, fax and internet
Postage
Cleaning and waste management
Stationery and printing
Hire of equipment
Equipment expenses
Equipment repairs,expenses and maintenance
Software licences and expenses
Premises repairs, renewals and
maintenance
Advertising and marketing
Depreciation & Amortisation in total for
Other legal and professional|**Current year**
**Total Funds**
**2023**
**£**
**219**
**24,212**
**17**
**-**
**686**
**596**
**2,184**
**698**
**1,480**
**-**
**7,895**
**2,199**
**1,099**
**4,098**
**11,746**
**-**
**710**
**26,745**
**660**
**35**
**1,025**|**Prior Year**
**Total Funds**
**2022**
**£**
**249**
**23,206**
**414**
**216**
**4,098**
**428**
**2,365**
**582**
**416**
**840**
**7,381**
**3,167**
**1,058**
**2,332**
**13,502**
**325**
**1,080**
**21,528**
**-**
**24**
**625**|
||**86,304**
**86,304**|**83,836**|
|||**83,836**|
||||
32
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
|**_Prior Year_**
**_Premises Expenses_**
Rates and water charges
Rent and rates
Light heat and power
Cleaning and waste management
Premises repairs, renewals and
maintenance
Property insurance
**_Administrative overheads_**
Telephone, fax and internet
Postage
Stationery and printing
Shipping, freight and delivery
Membership subscriptions
Equipment expenses
Hire of equipment
Software licences and expenses
Advertising and marketing
Equipment repairs,expenses and
maintenance
Accountancy fees other than
examination or audit fees
Management fees
**_Financial costs_**
Bank charges
Depreciation & Amortisation in
total for the period
**_Support costs before_**
**_reallocation_**
**_Professional fees paid to advisors other than the_**
**_auditor or examiner_**
**Total support costs - Prior Year**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
249
23,206
414
216
4,098
428
2,042
483
416
840
7,381
3,167
1,058
1,426
12,433
325
1,080
21,528
24
625|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
-
-
-
-
-
323
99
-
-
-
-
-
906
1,069
-
-
-
-
-
**2,397**
**2,397**|**Prior Year**
**Total Funds**
**2022**
**£**
**249**
**23,206**
**414**
**216**
**4,098**
**428**
**2,365**
**582**
**416**
**840**
**7,381**
**3,167**
**1,058**
**2,332**
**13,502**
**325**
**1,080**
**21,528**
**24**
**625**|
|---|---|---|---|
||**81,439**||**83,836**
**83,836**|
||**81,439**|||
The basis of allocation of costs between activities is described under accounting policies
33
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **26 Other Expenditure - Governance costs**
|**_Current Year_**
Independent Examiner's fees
**Total Governance costs**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
-|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
**-**|**Current year**
**Total Funds**
**2023**
**£**
**-**
**-**|**Prior Year**
**Total Funds**
**2022**
**£**
**420**|
|---|---|---|---|---|
||**-**|||**420**|
All the expenditure in the prior year was unrestricted.
## **27 Total Charitable expenditure**
|**Total Charitable expenditure**|||||
|---|---|---|---|---|
|**_Current Year_**
Total direct spending
**B2a**
Total charitable trading costs
**B2b**
Total grantmaking costs
**B2c**
Total support costs
**B2d**
Total Governance costs
**B2e**
**Total charitable expenditure**
**B2**
**_Prior Year_**
Total direct spending
**B2a**
Total charitable trading costs
**B2b**
Total grantmaking costs
**B2c**
Total support costs
**B2d**
Total Governance costs
**B2e**
**Total charitable expenditure**
**B2**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
46,402
7,874
25,000
83,172
-|**Current year**
**Restricted**
**Funds**
**2023**
**£**
25,102
-
-
3,132
-
**28,234**
**Prior Year**
**Restricted**
**Funds**
**2022**
**£**
10,585
-
-
2,397
-|**Current year**
**Total Funds**
**2023**
**£**
**71,504**
**7,874**
**25,000**
**86,304**
**-**
**190,682**
**Prior Year**
**Total Funds**
**2022**
**£**
**47,250**
**11,198**
**24,251**
**83,836**
**420**|**Prior Year**
**Total Funds**
**2022**
**£**
**47,250**
**11,198**
**24,251**
**83,836**
**420**|
||**162,448**|||**166,955**|
||**Prior Year**
**Unrestricted**
**Funds**
**2022**
**£**
36,665
11,198
24,251
81,439
420||||
||**153,973**|**12,982**|**166,955**||
34
## **Leukaemia & Myeloma Research UK Ltd**
**Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015**
## **28 Expenditure on raising funds and costs of investment management**
|**_Current Year_**
Agent's costs for fundraising
Fundraising publicity & marketing
Cost of fundraising activities
Fundraising trading costs
**Total fundraising costs**
**B1**|**Current year**
**Unrestricted**
**Funds**
**2023**
**£**
6,450
-
11,996
654|**Current year**
**Restricted**
**Funds**
**2023**
**£**
-
-
-
-
**-**|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2023**
**2022**
**£**
**£**
**6,450**
**4,945**
**-**
**480**
**11,996**
**2,764**
**654**
**906**|
|---|---|---|---|
||**19,100**||**19,100**
**9,095**|
All the expenditure in the prior year was unrestricted.
35